**Background of NTMT1 Antibody**
NTMT1 (N-terminal methyltransferase 1), also known as METTL11A or NRMT1. is an enzyme responsible for catalyzing the methylation of protein N-terminal α-amino groups, a conserved post-translational modification in eukaryotes. This methylation primarily targets proteins with an N-terminal X-P-K/R motif, influencing their stability, localization, and interactions. NTMT1 plays critical roles in diverse biological processes, including DNA repair, chromosome segregation, and transcriptional regulation. Dysregulation of NTMT1 has been linked to cancers, developmental disorders, and neurodegenerative diseases, underscoring its therapeutic and diagnostic potential.
NTMT1 antibodies are immunological tools designed to detect and study the expression, localization, and function of NTMT1 in various experimental settings (e.g., Western blot, immunofluorescence, immunohistochemistry). These antibodies are typically developed using immunogenic peptides derived from conserved regions of the human NTMT1 protein. Validated NTMT1 antibodies aid in elucidating the enzyme's role in disease mechanisms and normal physiology. They are also essential for assessing NTMT1 levels in clinical samples, offering insights into biomarker discovery and targeted therapy development. Specificity and cross-reactivity validation (e.g., using knockout controls) are crucial to ensure reliability in research applications.